Please ensure Javascript is enabled for purposes of website accessibility

Why Corcept Therapeutics Incorporated Stock Is Getting Clobbered Today

By George Budwell - Feb 5, 2018 at 3:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Corcept's flagship drug could be facing generic competition far sooner than expected.

What happened

Corcept Therapeutics (CORT -2.87%), an endocrine-oriented drugmaker, is having an exceptionally bad day today. The drugmaker's shares are in free fall, thanks to Teva Pharmaceutical Industries' (TEVA -4.63%) decision to file a U.S. marketing application for a generic version of the company's only marketed drug, Korlym, indicated for patients suffering from Cushing syndrome.

In response to this news, Corcept's shares were down by 24.6% on over three times the average daily volume at 2:15 p.m. EST. Teva's shares, on the other hand, are failing to respond to this positive regulatory development. The Israeli generic-drug giant's shares are down by 1.8% at this writing, and are largely sinking in lockstep with the broader markets today.

A surprised investor standing in front of a downward-trending chart

Image source: Getty Images.

So what

Teva is arguing that either its generic product won't infringe on Korlym's patents, or the branded drug's key patents are "invalid and/or are unenforceable." Not surprisingly, Corcept's management isn't buying this kitchen-sink argument, with the company set to "vigorously defend" Korlym's intellectual property.

Now what

As a patent dispute can take several years to resolve, the market appears to be overreacting to this particular piece of news. In other words, Teva could end up winning this patent dispute, but it won't happen anytime soon.

That being said, Corcept's shares have been trading at a sky-high premium for a while now, so a healthy pullback was likely coming down the pike anyways.

In all, this sizable downturn might actually represent an attractive entry point for risk-tolerant investors. Corcept, after all, should be able to successfully fend off Teva's patent challenge to continue generating industry-leading levels of top-line growth.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Corcept Therapeutics Incorporated Stock Quote
Corcept Therapeutics Incorporated
$24.38 (-2.87%) $0.72
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$7.83 (-4.63%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.